GLP-1 receptor agonists have become central managing type 2 diabetes and obesity. Their relevance in hepatology is now coming into sharper focus. In August 2025, the FDA approved Wegovy for treating metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis, using the accelerated approval pathway based on histologic surrogate endpoints.
Even as semaglutide establishes its role in this space, a parallel body of evidence is around alcohol use disorder and alcohol-associated liver disease. Together, these developments position GLP-1 receptor agonists as a drug class with potentially complementary roles across the spectrum of liver disease. Tap the link to read the full story. https://t.co/TsgqMQxbRN
Depression and anxiety are not isolated conditions.
This paper examines how the timing of depression across the life course may influence dementia risk and brain structure, reinforcing the need for earlier intervention.